AzTrials
AzTrials

Acute PancreatitisPAN-PROMISENCT03650062

Patient-reported Outcome Scale in Acute Pancreatitis

An observational study of Acute Pancreatitis, run by Enrique de-Madaria at 26 sites in 14 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The PAN-PROMISE study (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis-an international proSpEctive cohort study) aims to measure an outcome variable in acute pancreatitis (AP) based in the patient´s experience. PAN-PROMISE is a cohort study involving patients with AP. Read more about this study

Who is it for?
Ages 18 to 79 years
Conditions the study is for
Acute Pancreatitis
How many people
525 participants
Where
26 sitesin 14 countries
Study dates
30 May 2017to 3 Feb 2019
How long will I take part?
1 Month
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 79 years
  • All sexes
  • Adult, Older adult

Study population: Consecutive patients admitted with acute pancreatitis in the participating centers.

Who may be able to join

  • Patients ≥18 and <80 years.
  • Karnofsky performance status previous to AP 100 (normal, no complaints, no evidence of disease), 90 (able to carry on normal activity; minor signs or symptoms of disease) or 80 (normal activity with effort; some signs or symptoms of disease).
  • Acute pancreatitis defined as at least 2 of the following 3 criteria: A) Typical abdominal pain, B) Elevation of amylase and/or lipase more than 3 times the upper limit of normality, and C) Imaging (preferably CT and/or MR) compatible with AP.
  • Written informed consent.

Who cannot join

  • Time between onset of symptoms and presentation in the emergency room (ER) greater than 48 hours (we do not consider as onset of symptoms previous self-limited heraldic biliary pain)
  • Recruitment >24h after presentation in the ER
  • Karnofsky performance status previous to AP 70 (Cares for self; unable to carry on normal activity or to do active work) or less
  • Inability to express or understand the instructions of the study (severe congenital or acquired intellectual deficit).
  • More than 1 previous episode of AP.
  • Chronic pancreatitis.
  • Presence of diseases or conditions different from AP that may interfere with the scale: other causes of abdominal pain (especially acute cholecystitis; Note: choledocholithiasis-acute cholangitis is not an exclusion criteria), obstruction of the digestive tract (peptic pyloric stenosis, gastrointestinal anastomotic stenosis, diabetic gastroparesis, gastrointestinal neoplasia...), nausea-vomiting (brain tumor, chemotherapy...) or weakness (pre-existing anemia with Hb <9 mg/dL, heart failure or respiratory insufficiency associated with minimal effort dyspnea, or domiciliary treatment with O2, advanced neoplasms or other debilitating diseases).

Trial locations and contacts

26 sites in 14 countries.

26 sites in 14 countries

Spain10 sites
  • Hospital General Universitario de Alicante

    Alicante, 03550

  • Hospital Santa María

    Lleida

  • Hospital San Pedro

    Logroño

  • Hospital Central de Asturias

    Oviedo

  • Complejo Hospitalario de Navarra

    Pamplona

  • Complejo Hospitalario Universitario de Santiago

    Santiago de Compostela

  • Hospital Clínico Universitario de Valladolid

    Valladolid

  • Hospital Alvaro Cunqueiro

    Vigo

  • Hospital Lozano Blesa

    Zaragoza

  • Hospital Miguel Servet

    Zaragoza

Other trials in Spain

Hungary2 sites
  • Centre for Translational Medicine, University of Pécs

    Pécs

  • University of Szeged

    Szeged

Other trials in Hungary

Portugal2 sites
  • Fernando Fonseca Hospital

    Amadora

  • Centro Hospitalar Tondela-Viseu

    Viseu

Other trials in Portugal

Romania2 sites
  • Emergency Hospital of Bucharest

    Bucharest

  • Iuliu Hatieganu University of Medicine and Pharmacy

    Cluj-Napoca

Other trials in Romania

United States1 site
  • Johns Hopkins Medical Center

    Baltimore, Maryland, 21287

Other trials in United States

Colombia1 site
  • Hospital Universitario San Ignacio

    Bogotá

Other trials in Colombia

Greece1 site
  • Attikon University Hospital

    Athens

Other trials in Greece

Italy1 site
  • Dip.Medicina-Università degli Studi di Verona

    Verona

Other trials in Italy

Lithuania1 site
  • Vilnius University

    Vilnius

Other trials in Lithuania

Mexico1 site
  • Servicio de Cirugía General, IMSS, León

    Guanajuato City

Other trials in Mexico

Poland1 site
  • Medical University of Łódź

    Lodz

Other trials in Poland

Russia1 site
  • Immanuel Kant Baltic Federal University

    Kaliningrad

Other trials in Russia

South Korea1 site
  • Konkuk University School of Medicine

    Seoul

Other trials in South Korea

Ukraine1 site
  • Medical Institute Lviv

    Lviv

Other trials in Ukraine

About this study

Official title: Patient-reported Outcome Scale in Acute pancreatitis-an International Prospective Cohort Study

The PAN-PROMISE study (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis-an international proSpEctive cohort study) aims to measure an outcome variable in acute pancreatitis (AP) based in the patient´s experience. PAN-PROMISE is a cohort study involving patients with AP. The patient´s symptom perception will be compared with the opinion of the clinicians and with clinical outcomes.

Read the detailed description

Currently, the most important outcome variables in Acute Pancreatitis (AP) are persistent organ failure (POF) and mortality, according to the physician point of view. These variables occur infrequently (<10 and <5% respectively) (Sternby et all, see "References"), therefore, studies designed to assess the effectiveness of new treatments for AP to decrease POF or mortality require a very large sample of patients, which is unfeasible. Currently, clinical trials addressing the management of AP do not take into account Patient Reported Outcome Measures.

PROMS (Patient Reported Outcome Measures) have been defined as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else (first link in "References"). PROMS are gaining importance as a tool to design outcome variables. This kind of measurement has been recently included in the quality assesment approaches (Crossing the Quality Chasm: A New Health System for the 21st Century, see "References"), being PROMS a useful tool to improve the triple aim framework of better quality, appropriate utilization, and enhanced patient experience (second link in "References"). The aim of PAN-PROMISE is to incorporate an outcome variable in AP based in the patient´s experience. For this purpose the investigators involved in this project have developed a new instrument based on symptoms found to be important for the patient. This new instrument is intended to be a simple quantitative variable, relevant for the patient, that can be useful to test new treatments for AP without the need for a very large sample size, fulfilling the requirements of the triple aim framework by incorporating an outcome measurement defined by the patient.

Hypothesis:

  • PROMS must be incorporated to patient care and research in AP to improve the triple aim framework of better quality, appropriate utilization, and enhanced patient experience
  • A PROMS scale is a useful outcome variable to investigate new treatments in AP
  • The different severity categories of the revision of the Atlanta Classification (RAC) have different scores on the PROMS scale in acute pancreatitis: severe greater than moderate and mild, moderate greater than mild.
  • Increasing scores on the PROMS scale are associated to increased morbidity

Aims:

  • Main aim 1: to measure patient´s symptoms during an episode of AP and to correlate the intensity of these symptoms to clinical outcomes
  • Main aim 2: to design and validate a PROMS scale in AP intended to be an suitable outcome variable in future trials addressing the management of AP

Methods

Part 1: development of the PAN-PROMISE instrument The PAN-PROMISE research team developed a qualitative study in which three nominal groups were conducted, two with patients who had suffered an acute pancreatitis (AP) in hospitals in Alicante (Universitarian General Hospital)), and Valencia (Clinic Hospital), Spain and another with clinicians from the Alicante region with experience in treating patients with AP. Participants were asked about the symptoms that cause the most discomfort and concern to patients at three specific times: before receiving treatment for AP, during hospital admission and after discharge. The perspectives of patients and professionals were compared. From the information gathered in the nominal groups, a first version of a PROMS questionnaire was elaborated and shared with an international group of gastroenterologists, experienced in the management of pancreatitis, from 4 countries (Germany, Spain, USA, India and Turkey) through an online application to determine to what extent these experiences were shared in frequency and intensity by patients in these different countries. With all this information, a PROMS instrument was generated.

Part 2: measurement of patient´s symptoms in an international cohort study

2.1 Design. The PAN-PROMISE instrument is being measured in patients participating in a multicenter international prospective cohort study. Consecutive adult patients with AP are eligible after signed informed consent.

2.2 Center recruitment The PAN-PROMISE study has been endorsed by the Spanish Association of Pancreatology (AESPANC), the Spanish Association of Gastroenterology (AEG) and the International Association of Pancreatology (IAP); these associations shared the project with their members and through their social networks, calling for researchers and centers to join this initiative. PAN-PROMISE has also a webpage www.promisepancreatitis.com to promote center recruitment.

2.3 Patient registry PAN-PROMISE measurement will rely on a patient registry hosted in the Spanish Association of Gastroenterology (AEG) REDCap node. AEG offered this REDCap web-based online patient registry tool at no cost. Claudia Sánchez-Marin, a gastroenterologist, is on charge of quality control (data validation, data checks, contact with researchers to solve issues). The REDCap online registry was designed with logical rules to ensure good quality data entry, including mandatory fields to enter, logical ranges for quantitative variables, alarms if logical rules are not coherent (for example to have persistent organ failure but to classify the episode as mild or moderate), expanding fields only available in the presence of certain circumstances (for example, detailed organ failure description is only available if the patient had organ failure).

Keywords
Patient Reported Outcome Measures, Follow-Up Studies, Patient Outcome Assessment, Treatment Outcome, Pancreatitis, Acute Necrotizing
Medical subject headings
Pancreatitis, Pancreatitis, Acute Necrotizing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Severity of acute pancreatitis according to the revised Atlanta classification [incidence of local and/or systemic complications]

    Mild acute pancreatitis (no complications), moderately severe acute pancreatitis (local complications and/or transient (≤48h) organ failure and/or exacerbation of previous comorbidity), severe acute pancreatitis (persistent (>48h) organ failure) (see revised Atlanta classification, Banks et al, Gut 2013)

    Measured: Up to 15 days after hospital discharge from index hospital admission

  2. PAN-PROMISE patient reported outcome measurement instrument

    PROMISE SCALE (Patient-reported Outcome Scale in Acute pancreatitis) Each item is scored from 0 to 10 ( worst score in the last 24h): 0 none, 10: the highest possible intensity according to the patient

    1. Pain, especially in the abdomen, chest or back
    2. Abdominal distention (bloating, sensation of excess gas)
    3. Difficulty eating, sensation of food being stuck in the stomach
    4. Difficulty with bowel movements (constipation or straining on bowel movements)
    5. Nausea and/or vomiting
    6. Thirst
    7. Weakness, lack of energy, fatigue, difficulty moving

    Measured: From within 24h after admission to 15 days after discharge

Secondary outcomes (11)
  1. EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30) Version 3.0

    EORTC QLQ-C30, a widely used and validated quality of life scale, includes 28 questions with a four-point scale: "Not at all" (1 point), "A little" (2), "Quite a bit" (3) and "Very much." (4); 4 means an important impact on quality of life. The last 2 questions are scored from 1 (very poor) to 7 (excellent), being 7 indicative of excellent quality of life.

    Measured: 15 days after hospital discharge

  2. C-reactive protein

    A marker of inflammation

    Measured: 48 and 72h after recruitment

  3. Local complications (incidence of pancreatic/peripancreatic necrosis and acute peripancreatic fluid collections)

    Defined according to the revised Atlanta classification (Banks et al, Gut 2013)

    Measured: Up to 15 days after hospital discharge from index hospital admission

  4. Need for invasive treatment

    Endoscopic, percutaneous or surgical drainage or necrosectomy

    Measured: Up to 15 days after hospital discharge from index hospital admission

  5. Need for nutritional support

    Need for enteral and/or parenteral nutritional support

    Measured: Up to 15 days after hospital discharge from index hospital admission

  6. Admission in the Intensive Care Unit

    Need for intensive care support

    Measured: Up to 15 days after hospital discharge from index hospital admission

  7. Hospital stay

    Days, on index admission

    Measured: Up to 15 days after hospital discharge from index hospital admission

  8. Organ failure

    Transient and persistent organ failure defined according to the revised Atlanta classification (Banks et al, Gut 2013)

    Measured: Up to 15 days after hospital discharge from index hospital admission

  9. Mortality

    Mortality during index admission

    Measured: Up to 15 days after hospital discharge from index hospital admission

  10. Hospital readmission

    Hospital readmission due to symptom relapse or complications of index acute pancreatitis

    Measured: Up to 15 days after hospital discharge from index hospital admission

  11. Systemic Inflammatory Response Syndrome (SIRS)

    Presence of SIRS and persistent (>48h) SIRS

    Measured: Up to 15 days after hospital discharge from index hospital admission

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2018
  2. Study start30 May 2017
  3. Primary completion3 Feb 2019
  4. Study completion3 Feb 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
525 participants (actual)
Target duration
1 Month
IDs, dates and publications
ClinicalTrials.gov ID
NCT03650062
Sponsor's protocol ID
PI2016/69
Acronym
PAN-PROMISE
Status last verified
Feb 2019
First submitted
20 Aug 2018
Last updated
5 Feb 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The whole database will be offered to the study collaborators who actively recruited patients

Publications

  • Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US); 2001. Available from http://www.ncbi.nlm.nih.gov/books/NBK222274/

    PubMed 25057539
  • Sternby H, Bolado F, Canaval-Zuleta HJ, Marra-Lopez C, Hernando-Alonso AI, Del-Val-Antonana A, Garcia-Rayado G, Rivera-Irigoin R, Grau-Garcia FJ, Oms L, Millastre-Bocos J, Pascual-Moreno I, Martinez-Ares D, Rodriguez-Oballe JA, Lopez-Serrano A, Ruiz-Rebollo ML, Viejo-Almanzor A, Gonzalez-de-la-Higuera B, Orive-Calzada A, Gomez-Anta I, Pamies-Guilabert J, Fernandez-Gutierrez-Del-Alamo F, Iranzo-Gonzalez-Cruz I, Perez-Munante ME, Esteba MD, Pardillos-Tome A, Zapater P, de-Madaria E. Determinants of Severity in Acute Pancreatitis: A Nation-wide Multicenter Prospective Cohort Study. Ann Surg. 2019 Aug;270(2):348-355. doi: 10.1097/SLA.0000000000002766.

    PubMed 29672416
  • de-Madaria E, Sanchez-Marin C, Carrillo I, Vege SS, Chooklin S, Bilyak A, Mejuto R, Mauriz V, Hegyi P, Marta K, Kamal A, Lauret-Brana E, Barbu ST, Nunes V, Ruiz-Rebollo ML, Garcia-Rayado G, Lozada-Hernandez EE, Pereira J, Negoi I, Espina S, Hollenbach M, Litvin A, Bolado-Concejo F, Vargas RD, Pascual-Moreno I, Singh VK, Mira JJ. Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study. Gut. 2021 Jan;70(1):139-147. doi: 10.1136/gutjnl-2020-320729. Epub 2020 Apr 3.

    PubMed 32245906

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Pancreatitis, run by Enrique de-Madaria at 26 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 26 sites in Spain, Hungary, Portugal, Romania, United States and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Severity of acute pancreatitis according to the revised Atlanta classification [incidence of local and/or systemic complications] (time frame: Up to 15 days after hospital discharge from index hospital admission). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03650062, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in